| __timestamp | ADMA Biologics, Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9517014 | 51796000 |
| Thursday, January 1, 2015 | 7015946 | 72758000 |
| Friday, January 1, 2016 | 7688238 | 61008000 |
| Sunday, January 1, 2017 | 6229587 | 66962000 |
| Monday, January 1, 2018 | 3926120 | 84888000 |
| Tuesday, January 1, 2019 | 2343848 | 107068000 |
| Wednesday, January 1, 2020 | 5907013 | 122964000 |
| Friday, January 1, 2021 | 3646060 | 208808000 |
| Saturday, January 1, 2022 | 3613764 | 253297000 |
| Sunday, January 1, 2023 | 3300000 | 216566000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, BioCryst Pharmaceuticals has consistently outpaced ADMA Biologics in R&D investment. In 2022, BioCryst's R&D expenses were approximately 70% higher than in 2014, reflecting a strategic focus on expanding their drug pipeline. In contrast, ADMA Biologics saw a decline of about 65% in their R&D spending over the same period, indicating a potential shift in strategic priorities. This divergence highlights the varying approaches these companies take towards innovation and growth. As the biotech industry continues to evolve, understanding these spending patterns provides valuable insights into each company's future potential and market positioning.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs ADMA Biologics, Inc.
Analyzing R&D Budgets: Bio-Techne Corporation vs BioCryst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Grifols, S.A. and ADMA Biologics, Inc.
Research and Development: Comparing Key Metrics for Opthea Limited and BioCryst Pharmaceuticals, Inc.
Research and Development Investment: ADMA Biologics, Inc. vs Xenon Pharmaceuticals Inc.
Research and Development Investment: ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Xencor, Inc.
Research and Development Investment: Viking Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
R&D Spending Showdown: Amicus Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Analyzing R&D Budgets: Mesoblast Limited vs BioCryst Pharmaceuticals, Inc.
R&D Insights: How BioCryst Pharmaceuticals, Inc. and Evotec SE Allocate Funds